87769-64-0

Usage

Uses

Used in Pharmaceutical Industry:
2-Benzyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one is used as a potential drug candidate for its antioxidant, antifungal, and anticancer properties. Its diverse biological activities make it a valuable target for the development of new medications to treat various diseases and conditions.
Used in Medical Research:
In the field of medical research, 2-benzyl-6-phenyl-4,5-dihydropyridazin-3(2H)-one serves as a subject of study for its potential applications in treating diseases. Its unique structure and pharmacological properties provide a foundation for exploring new therapeutic approaches and understanding the underlying mechanisms of its biological effects.

Upstream product

• 2051-95-8 succinylbenzene 
• 71-43-2 benzene 
• 1011-46-7 6-phenyl-2,3,4,5-tetrahydropyridazin-3-one 
• 100-39-0 benzyl bromide 
• 1444833-44-6 C₁₇H₁₅BrN₂O 
• 1444833-15-1 C₁₇H₁₄Cl₂N₂O 
• 1444832-65-8 C₁₇H₁₅ClN₂O 
• 1073-62-7 N-benzylhydrazine hydrochloride 

Downstream Products

• 2166-31-6 6-phenylpyridazin-3(2H)-one 
• 89868-16-6 6-phenyl-4-pyridazol 
• 89868-14-4 4-chloro-6-phenylpyridazin-3(2H)-one 
• 89868-15-5 3-(dimethylamino)-6-phenyl-4-pyridazinol 
• 89868-00-8 (3-Chloro-6-phenyl-pyridazin-4-yl)-dimethyl-amine 
• 89868-07-5 4-(dimethylamino)-6-phenyl-3(2H)-pyridazinone 
• 89868-02-0 Butyl-(3-chloro-6-phenyl-pyridazin-4-yl)-amine 
• 89868-09-7 4-Butylamino-6-phenyl-2H-pyridazin-3-one 
• 89868-01-9 N'-(3-Chloro-6-phenyl-pyridazin-4-yl)-N,N-dimethyl-propane-1,3-diamine 
• 89868-11-1 4-Morpholin-4-yl-6-phenyl-2H-pyridazin-3-one 
• 89868-10-0 6-Phenyl-4-thiomorpholin-4-yl-2H-pyridazin-3-one 
• 89868-04-2 4-(3-Chloro-6-phenyl-pyridazin-4-yl)-morpholine 
• 89868-05-3 4-(3-Chloro-6-phenyl-pyridazin-4-yl)-thiomorpholine 
• 89868-03-1 3-Chloro-4-(4-methyl-piperazin-1-yl)-6-phenyl-pyridazine 

Relevant academic research and scientific papers

Brine Shrimp (Artemia salina) Lethality Bioassay of Some 2-(Alkyl/Aryl)-6-Phenyl-4,5-Dihydropyridazin-3(2H)-one Derivatives

A series of pyridazinone derivatives, 2-(alkyl/aryl)-6-phenyl-4,5-dihydropyridazin-3(2H)-ones (3a-h), was synthesized from 6-phenyl-4,5-dihydropyridazin-3(2H)-one (2). Compound 2 was synthesized from benzoylpropionic acid (1). The synthesized compounds were characterized on the basis of their spectral (infrared, proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance, and mass spectra) and elemental analytical data. The compounds 2 and 3a-h and potassium dichromate (as reference drug) were tested at the dose level of 10, 20, and 30 μg/mL. Compounds 3d and 3b exhibited potent brine shrimp lethality with LC50values of 4.023 μg and 4.20 μg. Other compounds 3g, 3f, 3c, 3h, 2, 3a, and 3e also showed significant cytotoxic activity with LC50values of 13.91, 12.58, 11.91, 11.76, 10.58, 9.76, and 7.46 μg, respectively. The present study supports that brine shrimp bioassay is a simple, reliable, and suitable method for estimation of bioactivity of synthesized compounds and provides support for their use in medicine.

A copper-catalyzed aerobic cascade dehydrogenative- dehalogenative reaction

A copper-catalyzed cascade dehydrogenative and dehalogenative reaction of halogenated 6-phenyl-4,5-dihydropyridazin-3(2H)-ones to 6-phenylpyridazin-3(2H)- ones has been developed. Moreover, the catalytic system consisting of copper(II) acetate/sodium carbonate/pyridine exhibits high reactivity and selectivity with oxygen as the terminal oxidant. Copyright

HETEROCYCLIC COMPOUND AND USE THEREOF

The present invention aims to provide a compound having a PDE inhibitory action and useful as a medicament for the prophylaxis or treatment of schizophrenia and the like. A compound represented by the formula (1x): wherein each symbol is as des

Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents

Substituted 6-phenyl-3(2H)-pyridazinone compounds are useful as cardiotonic agents. Said compounds cause a significant increase in myocardial contractility in the anesthetized dog. Said compounds are produced by reacting substituted γ-oxobenzenebutanoic acids with suitably substituted hydrazines to provide 6-phenyl-4,5-dihydro-3(2H)-pyridazinones which are dehydrogenated to the desired product. The intermediate 6-phenyl-4,5-dihydro-3(2H)-pyridazinones are themselves useful as cardiotonic agents.